






**MIOF**  
Middle East and North Africa Immuno-Oncology Forum



# MIOF II

The “Middle East and North Africa Immuno-Oncology Forum”

American University of Beirut Medical Center



**6-7 November 2020**

**Hybrid Meeting**

ACC Multipurpose Rooms,  
AUBMC, Beirut-Lebanon





# MIOF

Middle East and North Africa Immuno-Oncology Forum

**Format:** Case Studies and Polling Questions

**keynote Lecture:** Cancer Management in the Era of COVID-19

## GENERAL SESSION

1. Understanding and Overcoming Resistance to Immunotherapy
2. Rise of the Combinations in Targeted Therapies
3. The Emerging Liquid Biopsy Technology Landscape
4. Determining Treatment Based on Tumor PD-L1: Which Tumors? Which Assays/Thresholds?

## LUNG, HEAD & NECK

1. Optimizing Treatment for Nasopharyngeal Carcinoma
2. Integrating Genetic and Genomic Testing Into thoracic oncology
3. Immuno-oncology in Locally Advanced Lung Cancer
4. Immunotherapy in Metastatic NSCLC
5. Treating Patients with Lung Cancer When Immunotherapy Is No Longer an Option

## GU

1. Treatment Options for Metastatic Castration-Sensitive Prostate Cancer
2. Immune Checkpoint Blockade for Metastatic Castration-Resistant Prostate Cancer
3. Frontline Therapy for Advanced renal cell carcinoma: Is Two Better Than One?
4. Advanced Bladder Cancer - Role of Immunotherapy and Chemotherapy

## GI

1. 2020 Treatment Approach for mCRC: Moving Away from a One-Size-Fits-All Approach
2. Advanced Esophagogastric Cancer - Where to Fit Immunotherapy
3. Immunotherapy: A Path to Progress in Pancreaticobiliary Cancer
4. Systemic therapy for hepatocellular carcinoma



# MIOF

Middle East and North Africa Immuno-Oncology Forum

## BREAST

1. Neoadjuvant Therapy and Its Impact on Adjuvant Therapy for TNBC
2. Neoadjuvant and Adjuvant Options for High-Risk, HER2-Positive Breast Cancer
3. Combinations to Enhance the Efficacy of Hormonal Therapy in mBC.

## OVARIAN

1. Making Sense of Maintenance in Ovarian Cancer: PARP Maintenance: Who, When, How, and Why
2. Overview of Immunotherapeutic Approaches in Ovarian Cancer

## SKIN

1. Immunotherapy Advances in Cutaneous Squamous Cell and Basal Cell Carcinomas
2. Neoadjuvant therapy in advanced melanoma

## HEMATOLOGY

1. Multiple myeloma: Immunotherapy for Myeloma: Past, Present, Future.
2. CLL: Targeted Therapies vs Monoclonal Antibodies.
3. ALL: Conventional vs Futures Approaches for ALL Targeted Therapies in Allo-HSCT
4. Lymphoma: HSCT, CAR-T and Clinical Practice.
5. AML/MDS: Emerging Immunotherapies, Venetoclax-Based Regimens and Targeted Therapies in AML.
6. CML: Current CML Treatments: Which TKI to Choose?
7. CAR T-Cell Therapy: Strategies to Expand Access
8. Immunotherapy for Childhood Acute Lymphoblastic Leukemia (Studying Blinatumomab in Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia and High-Risk Features)

Organized by:



### LEBANON

4<sup>th</sup> Floor, Qubic Center  
Daoud Ammoun Street  
Horsh Tabet - Sin El Fil  
P.O. Box: 90-361 Beirut  
Tel: +961 1 510880/1/2/3  
Mobile: +961 71 103123

### UAE

DMCC Business Centre  
Almas Tower  
Jumeirah Lakes  
Dubai, United Arab Emirates  
Unit No: 3820  
Mobile: +971 50 9110475

### KUWAIT

Mezzanine floor,  
Aliya Complex  
Salem Al Mubarak St  
Block 2, Salmiya - Kuwait  
Tel: +965 6556 7669

